Clinical Trial VICCMEL0759

Title

A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma

Principal Investigator(s)

Jeffrey Sosman

Details

  • Protocol No. VICCMEL0759
  • Open Date: 08/01/2008
  • Staging: Phase II
  • Age Group: Adults
  • Scope: Local
  • Objective: To determine the response rate of patients with metastatic mucosal or acral/lentiginous melanoma to treatment with SU011248. To determine the time to progression of patients with metastatic mucosal or acral/lentiginous melanoma to treatment with SU011248
  • Disease Sites: Melanoma
  • Therapies: Chemotherapy - cytotoxic
  • Drugs: SU011248 (Sunitinib); Sunitinib
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00577382
  • Secondary Protocol No: SU011248

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.